Principles of diagnosis of ovarian neoplasms — minimization of errors

封面


如何引用文章

全文:

详细

Ovarian cancer mortality rates hold a leading position among women’s cancer, which is primarily associated with the pathogenetic features of ovarian cancer, the heterogeneity of the disease, the lack of effective screening and diagnostic methods for early cancer detection. The causes of most ovarian tumors remain unknown. Ovarian benign tumors and tumor-like formations are not among the risk factors of ovarian cancer. The purpose of this literature review is to highlight the latest data from world expert organizations on the possibilities of ovarian neoplasm diagnosis and treatment.

作者简介

Anna Protasova

Saint Petersburg State University; V.A. Almazov National Medical Research Center; North-Western State Medical University named after I.I. Mechnikov; AVA-PETER Ltd.

编辑信件的主要联系方式.
Email: protasova1966@yandex.ru

MD, PhD, DSci (Medicine), Professor. The Department of Oncology, Medical Faculty; Professor. The Department of Obstetrics and Gynecology; Professor. The Department of Oncology; the Head of the Department of Oncology

俄罗斯联邦, Saint Petersburg

Anna Tsypurdeyeva

Saint Petersburg State University; The Research Institute of Obstetrics, Gynecology, and Reproductology named after D.O. Ott

Email: tsypurdeevan@mail.ru

MD, PhD, Associate Professor The Department of Obstetrics, Gynecology, and Reproductive Sciences, Medical Faculty; Senior Researcher The Department of Gynecology with the Operating Unit

俄罗斯联邦, Saint Petersburg

Natalia Tsypurdeyeva

The Research Institute of Obstetrics, Gynecology, and Reproductology named after D.O. Ott

Email: tsypurdeevan@mail.ru

MD, PhD, Researcher

俄罗斯联邦, Saint Petersburg

Irina Solntseva

North-Western State Medical University named after I.I. Mechnikov; AVA-PETER Ltd.

Email: tsypurdeevan@mail.ru

MD, PhD, Associate Professor The Department of Radiology and Radiotherapy

俄罗斯联邦, Saint Petersburg

参考

  1. Гинекология: руководство для врачей / Под ред. В.Н. Серова, Е.Ф. Кира. – М.: Литтерра, 2008. – 840 с. [Ginekologiya: rukovodstvo dlya vrachey. Ed. by V.N. Serov, E.F. Kira. Moscow: Litterra; 2008. 840 p. (In Russ.)]
  2. Министерство здравоохранения Российской Федерации. Диагностика и лечение доброкачественных новообразований яичников с позиции профилактики рака: клинические рекомендации Министерства здравоохранения Российской Федерации (протокол лечения). – M., 2018. – 48 с. [Ministerstvo Zdravookhraneniya Rossiyskoy Federatsii. Diagnostika i lechenie dobrokachestvennykh novoobrazovaniy yaichnikov s pozitsii profilaktiki raka: klinicheskie rekomendatsii Ministerstva Zdravookhraneniya Rossiyskoy Federatsii (protokol lecheniya). Moscow; 2018. 48 p. (In Russ.)]
  3. Emedicine.medscape.com [Internet] Teng N, Rivlin ME. Adnexal Tumors Treatment & Management. Medscape. [cited 25 Mar 2019]. Available from: https://emedicine.medscape.com/article/258044-treatment.
  4. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2016 году. – М., 2018. – 250 с. [Kaprin AD, Starinskiy VV, Petrova GV. Zlokachestvennye novoobrazovaniya v Rossii v 2016 godu. Moscow; 2018. 250 p. (In Russ.)]
  5. El Din AA, Badawi MA, Aal SE, et al. DNA cytometry and nuclear morphometry in ovarian benign, borderline and malignant tumors. Open Access Maced J Med Sci. 2015;3(4):537-544. https://doi.org/10.3889/oamjms.2015.104.
  6. Zhu Q, Wu X, Wang X. Differential distribution of tumor-associated macrophages and Treg/Th17 cells in the progression of malignant and benign epithelial ovarian tumors. Oncol Lett. 2017;13(1):159-166. https://doi.org/10.3892/ol.2016.5428.
  7. Bray F, Ferlay J, Soerjomataram I, et al. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries: Global Cancer Statistics 2018. CA Cancer J Clin. 2018;68(suppl 8). https://doi.org/10.3322/caac.21492.
  8. Seer.cancer.gov [Internet]. Cancer Stat Facts: Ovarian Cancer [cited 25 Mar 2019]. Available from: http://www.seer.cancer.gov/statfacts/html/ovary.html.
  9. Nccn.org [Internet]. NCCN. Org. Ovarian cancer. Version 2. 2018 [cited 25 Mar 2019]. Available from: https://www.nccn.org/patients/.
  10. Carroll JC, Cremin C, Allanson J, et al. Hereditary breast and ovarian cancers. Can Fam Physician. 2008;54(12):1691-1692.
  11. King MC, Marks JH, Mandell JB, New York Breast Cancer Study G. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302(5645):643-646. https://doi.org/10.1126/science.1088759.
  12. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25(11):1329-1333. https://doi.org/10.1200/JCO.2006.09.1066.
  13. Paluch-Shimon S, Cardoso F, Sessa C, et al. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Ann Oncol. 2016;27(suppl 5):v103-v110. https://doi.org/10.1093/annonc/mdw327.
  14. Prat J, Ribe A, Gallardo A. Hereditary ovarian cancer. Hum Pathol. 2005;36(8):861-870. https://doi.org/10.1016/j.humpath.2005.06.006.
  15. Jazaeri AA. Molecular profiles of hereditary epithelial ovarian cancers and their implications for the biology of this disease. Mol Oncol. 2009;3(2):151-156. https://doi.org/10.1016/j.molonc.2009.01.001.
  16. Hall MJ, Reid JE, Burbidge LA, et al. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer. 2009;115(10):2222-2233. https://doi.org/10.1002/cncr.24200.
  17. Ben David Y, Chetrit A, Hirsh-Yechezkel G, et al. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol. 2002;20(2):463-466. https://doi.org/10.1200/JCO.2002.20.2.463.
  18. Ueland FR, Fredericks NI. Ovarian masses: Surgery or surveillance? OBG Manag. 2018;30(6):17-26.
  19. Кузнецова Е.П., Серебренникова К.Г. Современные методы диагностики опухолевидных образований и доброкачественных опухолей яичника // Фундаментальные исследования. – 2010. – № 11. – C. 78–83. [Kuznetsova EP, Serebrennikova KG. Sovremennye metody diagnostiki opukholevidnykh obrazovaniy i dobrokachestvennykh opukholey yaichnika. Fundamental’nye issledovaniya. 2010;(11):78-83. (In Russ.)]
  20. Glanc P, Benacerraf B, Bourne T, et al. First International Consensus Report on Adnexal Masses: Management Recommendations. J Ultrasound Med. 2017;36(5):849-863. https://doi.org/10.1002/jum.14197.
  21. Levine D, Brown DL, Andreotti RF, et al. Management of asymptomatic ovarian and other adnexal cysts imaged at US: Society of Radiologists in Ultrasound Consensus Conference Statement. Radiology. 2010;256(3):943-954. https://doi.org/10.1148/radiol.10100213
  22. Modesitt, S. Risk of malignancy in unilocular ovarian cystic tumors less than 10 centimeters in diameter. Obstet Gynecol. 2003;102(3):594-599. https://doi.org/10.1016/s0029-7844(03)00670-7.
  23. Andreotti RF, Timmerman D, Benacerraf BR, et al. Ovarian-Adnexal Reporting Lexicon for Ultrasound: A White Paper of the ACR Ovarian-Adnexal Reporting and Data System Committee. J Am Coll Radiol. 2018;15(10):1415-1429. https://doi.org/10.1016/j.jacr.2018.07.004.
  24. Pavlik EJ, Ueland FR, Miller RW, et al. Frequency and disposition of ovarian abnormalities followed with serial transvaginal ultrasonography. Obstet Gynecol. 2013;122(2 Pt 1):210-217. https://doi.org/10.1097/AOG.0b013e318298def5.
  25. Sharma A, Apostolidou S, Burnell M, et al. Risk of epithelial ovarian cancer in asymptomatic women with ultrasound-detected ovarian masses: a prospective cohort study within the UK collaborative trial of ovarian cancer screening (UKCTOCS). Ultrasound Obstet Gynecol. 2012;40(3):338-344. https://doi.org/10.1002/uog.12270.
  26. Saunders BA, Podzielinski I, Ware RA, et al. Risk of malignancy in sonographically confirmed septated cystic ovarian tumors. Gynecol Oncol. 2010;118(3):278-282. https://doi.org/10.1016/j.ygyno.2010.05.013.
  27. Kaijser J, Bourne T, Valentin L, et al. Improving strategies for diagnosing ovarian cancer: a summary of the International Ovarian Tumor Analysis (IOTA) studies. Ultrasound Obstet Gynecol. 2013;41(1):9-20. https://doi.org/10.1002/uog.12323.
  28. Timmerman D, Testa AC, Bourne T, et al. Simple ultrasound-based rules for the diagnosis of ovarian cancer. Ultrasound Obstet Gynecol. 2008;31(6):681-690. https://doi.org/10.1002/uog.5365.
  29. Elder JW, Pavlik EJ, Long A, et al. Serial ultrasonographic evaluation of ovarian abnormalities with a morphology index. Gynecol Oncol. 2014;135(1):8-12. https://doi.org/10.1016/j.ygyno.2014.07.091.
  30. Spencer JA, Forstner R, Cunha TM, Kinkel K. ESUR guidelines for MR imaging of the sonographically indeterminate adnexal mass: an algorithmic approach. Eur Radiol. 2009;20(1):25-35. https://doi.org/10.1007/s00330-009-1584-2.
  31. Bazot M, Darai E, Nassar-Slaba J, et al. Value of magnetic resonance imaging for the diagnosis of ovarian tumors: a review. J Comput Assist Tomogr. 2008;32(5):712-723. https://doi.org/10.1097/RCT.0b013e31815881ef.
  32. Valentini AL, Gui B, Micco M, et al. benign and suspicious ovarian masses-mr imaging criteria for characterization: pictorial review. J Oncol. 2012;2012:481806. https://doi.org/10.1155/2012/481806.
  33. Jeong YY, Outwater EK, Kang HK. Imaging evaluation of ovarian masses. Radiographics. 2000;20(5):1445-1470. https://doi.org/10.1148/radiographics.20.5.g00se101445.
  34. Buamah P. Benign conditions associated with raised serum CA-125 concentration. J Surg Oncol. 2000;75(4):264-265. https://doi.org/10.1002/1096-9098(200012)75:4<264::aid-jso7>3.0.co;2-q.
  35. Miralles C, Orea M, Espana P, et al. Cancer antigen 125 associated with multiple benign and malignant pathologies. Ann Surg Oncol. 2003;10(2):150-154. https://doi.org/10.1245/aso.2003.05.015.
  36. Skates SJ, Xu FJ, Yu YH, et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer. 1995;76(10 Suppl):2004-2010. https://doi.org/10.1002/1097-0142(19951115)76:10+<2004::aid-cncr2820761317>3.0.co;2-g.
  37. Skates SJ, Menon U, MacDonald N, et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol. 2003;21(10 Suppl):206s-210s. https://doi.org/10.1200/JCO.2003.02.955.
  38. Menon U, Skates SJ, Lewis S, et al. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol. 2005;23(31):7919-7926. https://doi.org/10.1200/JCO.2005.01.6642.
  39. Hellstrоm I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003;63(13):3695-3700.
  40. Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108(2):402-408. https://doi.org/10.1016/j.ygyno.2007.10.017.
  41. Lycke M, Kristjansdottir B, Sundfeldt K. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index. Gynecol Oncol. 2018;151(1):159-165. https://doi.org/10.1016/j.ygyno.2018.08.025.
  42. Teh BH, Yong SL, Sim WW, et al. Evaluation in the predictive value of serum human epididymal protein 4 (HE4), cancer antigen 125 (CA125) and acombination of both in detecting ovarian malignancy. Horm Mol Biol Clin Investig. 2018;35(1). https://doi.org/10.1515/hmbci-2018-0029.
  43. Jacobs I, Oram D, Fairbanks J, et al. A risk of malignancy index incorporating CA125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. BJOG. 1990;97(10):922-929. https://doi.org/10.1111/j.1471-0528.1990.tb02448.x.
  44. Moore RG, Jabre-Raughley M, Brown AK, et al. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol. 2010;203(3):228.e221-226. https://doi.org/10.1016/j.ajog.2010.03.043.
  45. Alanbay I, Akturk E, Coksuer H, et al. Comparison of risk of malignancy index (RMI), CA125, CA 19-9, ultrasound score, and menopausal status in borderline ovarian tumor. Gynecol Endocrinol. 2012;28(6):478-482. https://doi.org/ 10.3109/09513590.2011.633663.
  46. Karimi-Zarchi M, Mojaver SP, Rouhi M, et al. Diagnostic value of the risk of Malignancy Index (RMI) for detection of pelvic malignancies compared with pathology. Electron Physician. 2015;7(7):1505-1510. https://doi.org/10.19082/1505.
  47. Ульянова А.В., Пономарёва Ю.Н., Ашрафян Л.А. Совершенствование дифференциально-диагностических методов при новообразованиях яичников // Доктор Ру. – 2018. – № 6. – С. 40–43. [Ulyanova AV, Ponomaryova YN, Ashrafyan LA. Improving differential diagnosis techniques for ovarian neoplasms. Doktor Ru. 2018;(6):40-43. (In Russ.)]
  48. Bast RC, Jr, Badgwell D, Lu Z, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer. 2005;15 Suppl 3:274-281. https://doi.org/10.1111/j.1525-1438.2005.00441.x.
  49. Nosov V, Su F, Amneus M, et al. Validation of serum biomarkers for detection of early-stage ovarian cancer. Am J Obstet Gynecol. 2009;200(6):639.e631-635. https://doi.org/10.1016/j.ajog.2008.12.042.
  50. Cramer DW, Best RC, Clark C, et al. Abstract #LB-96: Phase III validation of ovarian cancer biomarkers in pre-diagnostic specimens from the PLCO screening trial. Proc Am Assoc Cancer Res. 2009:69(S9).
  51. Visintin I, Feng Z, Longton G, et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res. 2008;14(4): 1065-1072. https://doi.org/10.1158/1078-0432.CCR-07-1569.
  52. Edgell T, Martin-Roussety G, Barker G, et al. Phase II biomarker trial of a multimarker diagnostic for ovarian cancer. J Cancer Res Clin Oncol. 2010;136(7):1079-1088. https://doi.org/10.1007/s00432-009-0755-5.
  53. Yip P, Chen TH, Seshaiah P, et al. Comprehensive serum profiling for the discovery of epithelial ovarian cancer biomarkers. PLoS One. 2011;6(12):e29533. https://doi.org/10.1371/journal.pone.0029533.
  54. Никогосян С.О., Кузнецов В.В. Современная диагностика рака яичников // Российский онкологический журнал. – 2013. – № 5. – C. 52–55. [Nikogosyan SO, Kuznetsov VV. Modern diagnosis of ovarian cancer. Russian journal of oncology. 2013;(5):52-55. (In Russ.)]

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Protasova A.E., Tsypurdeyeva A.A., Tsypurdeyeva N.D., Solntseva I.A., 2019

Creative Commons License
此作品已接受知识共享署名 4.0国际许可协议的许可

##common.cookie##